UCLA researchers in the Division of Pulmonary Medicine at the School of Medicine uncovered a novel mechanism by which cancer cells adapt to glucose restriction and develop treatment resistance, and have in response developed a novel combination therapy to delay lung adenocarcinoma development while circumventing the development of aggressive behavior and drug resistance in lung cancer.
Contact UCLA Technology Development Group for more information.